Barclays Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has maintained an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and reduced the price target from $8 to $3.
April 10, 2024 | 7:29 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Pacific Biosciences but lowered the price target from $8 to $3.
The reduction in price target by Barclays, a major financial institution, suggests a bearish outlook on the stock's short-term price potential. This could lead to negative sentiment among investors and potentially lower stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100